Huntington's Disease - Drug Pipeline Landscape, 2023

Huntington's Disease - Drug Pipeline Landscape, 2023

Huntington's disease is a progressive brain disorder caused by a single defective gene on chromosome 4. This gene produces a protein called huntingtin, which is essential for normal brain development. However, when the gene is defective, it produces an abnormal form of huntingtin that is toxic to brain cells. The damage caused by the abnormal protein gradually destroys certain nerve cells in the brain, which leads to the characteristic symptoms of Huntington's disease.

The exact cause of the genetic defect that leads to Huntington's disease is unknown. However, it is thought to be due to a combination of environmental and genetic factors. Huntington's disease is usually diagnosed in adults between the ages of 30 and 50, but it can also occur in children and adolescents. The disease is usually fatal within 15 to 20 years of onset.

Huntington's disease patients may develop symptoms like uncontrolled movements (chorea), mood swings, depression, irritability, slowed movements and speech, loss of hand coordination and difficulty swallowing.

Healthcare provider will perform a physical exam and look for twitches and jerking as well as problems with balance, reflexes and coordination. Neurologist will also examine the family history. Blood test, genetic testing and imaging tests such as magnetic resonance imaging (MRI) and computed tomography (CT) scan can also be recommended.

Huntington's disease can be treated with medications like drugs to control movement, antipsychotic drugs, antidepressants, mood stabilizing drugs and other medications. Psychotherapy, speech therapy, physical therapy and occupational therapy can be used for treatment.

There are many clinical trials underway for Huntington's disease drug development. Some of these trials are testing new drugs, while others are testing new combinations of existing drugs. Many of these trials are small, and are focused on safety and tolerability rather than efficacy.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Huntington’s Disease treatment such as Deutetrabenazine, Pridopidine, LPM3770164, and others. Key players involved in the development of therapies to treat Huntington’s Disease are Luye Pharma, Prilenia Therapeutics, Asklepios, Biopharmaceuticals, and others. Six drugs are underpahse III stage, 10+ drugs are in Phase II clinical trials and five drugs are in Phase I clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development. In August 2022, Asklepios biopharmaceutical received clearance to conduct a Phase I/II trial of BV-101 for Huntington’s disease.

Report Highlights

Global Insight Service's, Huntington's Disease - Drug Pipeline Landscape, 2023 report provides an overview of the Huntington disease pipeline drugs. This report covers detailed insights on Huntington's Disease drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Huntington's Disease pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.